Pathologically Confirmed Cancer Refractory to Conventional Therapy
Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
NKGEN BiotechSNK02
Clinical Trials (1)
Total enrollment: 6 patients across 1 trials
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
Start: Aug 2023Est. completion: Apr 20246 patients
Phase 1Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space